AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Cellectis S.A.
Video analysis: CLLS
All videosNo video analysis for this stock yet. Request one from our team.
News: CLLS
Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Cellectis S.A. (NASDAQ: CLLS - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.00 and traded as low as $1.75. Cellectis shares last traded at $1.83, with a volume of 1,172,743 shares. Wall Street Analysts Forecast Growth CLLS has been
Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript
Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 200 points on Monday.
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 500 points on Monday.
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
